Medigus Broadens Availability of MUSE Through Distribution Agreement with MELEKIRMAK in Turkey, Azerbaijan and Georgia

Medical Device Investing

Medigus (NASDAQ:MDGS) (TASE:MDGS), a medical device company developing minimally invasive endosurgical tools and an innovator in direct visualization technology, today announced a distribution agreement in Turkey, Azerbaijan and Georgia with MELEKIRMAK (MELEKIRMAK SAĞLIK ÜRÜNLERİ TAŞIMACILIK GIDA TEKSTİL SANAYİ VE TİCARET LİMİTED ŞİRKETİ), a distributor of minimally invasive medical devices. As quoted in the press release: …

Medigus (NASDAQ:MDGS) (TASE:MDGS), a medical device company developing minimally invasive endosurgical tools and an innovator in direct visualization technology, today announced a distribution agreement in Turkey, Azerbaijan and Georgia with MELEKIRMAK (MELEKIRMAK SAĞLIK ÜRÜNLERİ TAŞIMACILIK GIDA TEKSTİL SANAYİ VE TİCARET LİMİTED ŞİRKETİ), a distributor of minimally invasive medical devices.

As quoted in the press release:

“The addition of MUSE™ to our product portfolio allows us to meet the preferences of both patients and physicians by offering a more cost-effective and minimally invasive option for treating GERD” said Ozan Akin, President, MELEKIRMAK. “MUSE™ addresses an unmet need in long-term treatment for GERD by addressing its root cause, making it a very valuable extension to our offerings.”

“Similar to the profile of GERD in other Western populations, its prevalence in Turkey is comparable – upward of 23%i, with higher risks for females and older individuals,” said Chris Rowland, Chief Executive Officer of Medigus. “We are excited to provide a treatment solution to this addressable market that may be more attractive than surgery or lifelong medication for patients suffering from GERD.”

Click here to read the full press release.

The Conversation (0)
×